Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
about
Structured treatment interruptions (STI) in chronic suppressed HIV infection in adultsEvaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptionsVisualization and quantification of simian immunodeficiency virus-infected cells using non-invasive molecular imaging.Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV modelSelective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID miceDrug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory TrialDNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent VirusThe HIV-1 pandemic: does the selective sweep in chimpanzees mirror humankind's future?Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefitIn vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.A human milk factor susceptible to cathepsin D inhibitors enhances human immunodeficiency virus type 1 infectivity and allows virus entry into a mammary epithelial cell line.The challenge of immune control of immunodeficiency virusStructured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assayLow-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells.Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies.Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection.Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection.Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapyHuman immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individualsStochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc.Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencingImmune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients.Cellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected SubjectsCD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway.Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infectionBreast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine.Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infectionSuppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory.Identification of HIV inhibitors guided by free energy perturbation calculations.HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppressionHIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent vHIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized miceModelling the evolution of HIV-1 virulence in response to imperfect therapy and prophylaxisTherapeutic vaccines against HIV infection.
P2860
Q24245709-5364BE0F-01F9-4FCF-8131-FEAD321D9117Q26777442-27862B0E-868E-4DCD-BA04-BDDC266137A7Q27323244-5BFE5346-6202-4DCB-91B2-51AE8EC5FAEFQ27335485-1F3A8BB3-ED59-49A5-9293-CC133B7FFD2AQ28343440-359A215C-63A8-4073-A760-DDBF538341FDQ28552171-A33AD425-20B6-4DE3-86BC-1D7714A9CD0CQ28554534-4D256910-3A14-48AE-9AA5-9F19FA305070Q30431054-18E75C67-BF2F-46C0-BCC1-EB7982647D60Q33698152-376B6931-A0DF-4478-976E-6600A8FF1505Q33724206-8D53012C-4BCE-48AC-A345-FBF2C9659F28Q33796739-A5B46556-7F10-47EF-A040-E587DDA385B8Q33854132-B69A70B0-F419-4BE7-A204-4147B490227BQ33949316-105BAE7D-F412-4021-B367-9031C53E1BB3Q33952995-B891F0DC-685E-4FE2-9FD2-15636ECD7CC8Q33971820-5E44F471-B39B-49E9-8EEF-57D8C6BB788BQ34028490-AC99DB41-6554-453C-A70B-E0299455D03FQ34255648-5540D4FE-B6E8-4BA1-A4E1-A59EAA119DD7Q34255654-5A842C49-A725-4D0C-A31E-64A9DEB5DE2CQ34282609-F8D714E3-059D-4507-B21B-6826B41DC6E6Q34328792-4C63C80C-C491-4DF6-BA15-546AFC95FF98Q34332119-0C2D3335-615E-4384-AACC-7183793FAEF7Q34348075-A1AA85B1-FCC3-4BD5-9D7A-5FCD9AC5FA20Q34359107-14610BDA-79AC-49F4-A9C0-FE3C5B96A1E4Q34367158-FB4BD45F-4D81-46E6-8B85-2AB86C29C557Q34567556-DD468DCB-1387-45A5-A8BF-97485BCB67DAQ34631665-7CFAB3ED-E782-405A-9A43-40403A92F05DQ34792090-2D908F45-4B37-4FFF-BAEE-8B2AE8D8FDABQ35115062-758FFA55-CE0B-43D6-BD43-C516BDC7DA17Q35207318-F5C32F95-9A62-4466-940A-7487EF4F5087Q35731394-26077A34-437D-44C9-AE00-14686A6A7527Q36052959-936E22CC-DE01-4BF7-B839-DD9B6F910123Q36099376-04D9793D-A452-4266-98BA-DCC49A28FCEDQ36315555-DE8973B2-479C-4481-B658-FBAE1275598EQ36602524-11062756-475B-40FA-911B-4009B7A1602BQ36708826-F9605610-05FE-4E2B-A1D8-9CA08663AC8CQ36781531-86EC3B9B-A2F9-4A13-9C01-E06C4537C90CQ36864918-B80D7EB1-6587-405C-9447-6F3EE07CB406Q37236504-EB456677-EE87-4ADC-A001-8FBB07C291CEQ37661125-4DA8B5E8-2C0D-47C1-BE22-E95857927941Q38013505-63153DEE-D707-4690-AC41-8D818A979C7D
P2860
Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Dynamics of viral load rebound ...... ective antiretroviral therapy.
@en
Dynamics of viral load rebound ...... ective antiretroviral therapy.
@nl
type
label
Dynamics of viral load rebound ...... ective antiretroviral therapy.
@en
Dynamics of viral load rebound ...... ective antiretroviral therapy.
@nl
prefLabel
Dynamics of viral load rebound ...... ective antiretroviral therapy.
@en
Dynamics of viral load rebound ...... ective antiretroviral therapy.
@nl
P2093
P1433
P1476
Dynamics of viral load rebound ...... ective antiretroviral therapy.
@en
P2093
O'Brien WA
Pantaleo G
P304
P356
10.1097/00002030-199907300-00002
P407
P577
1999-07-01T00:00:00Z